Secondary Logo

Journal Logo

Case Report

Novel management of critically induced polyneuropathy in intensive care patients

A case report of two patients

Ahuja, Vanita; Selvam, Selwin Rajan; Chander, Anjuman; Sawal, Nishit1,

Author Information
Journal of Anaesthesiology Clinical Pharmacology: Apr–Jun 2021 - Volume 37 - Issue 2 - p 290-292
doi: 10.4103/joacp.JOACP_427_19
  • Open

Abstract

Introduction

There has been tremendous growth in patients requiring critical care with severe infections. These patients during prolonged intensive care unit (ICU) stay develop critical illness polyneuropathy (CIP).[1] The incidence of CIP is 70% in individuals with sepsis or systemic inflammatory response syndrome[2] and 100% in multiple organ failure patients.[3] It is noted that 25% of the ICU patients developed weakness[4] and 49-84% electrophysiological abnormalities.[56] We describe two cases who developed complete motor weakness after a prolonged stay in ICU and were successfully managed with pyridostigmine and testosterone hormonal therapy initially and later with pyridostigmine only. The present case series highlights the need for assessment and early management of CIP in ICU patients.

Case History

Case 1

A 45-year-old female with uncontrolled diabetes mellitus, high-grade fever, and severe abdominal pain presented to the emergency department of our hospital. The septic shock with severe metabolic acidosis was managed with broad-spectrum antibiotics, fluids, inotropes, and sodium bicarbonate correction. During an emergency, laparotomy pus was drained from the pelvis and peritoneal drain was placed. Postoperatively, the patient was shifted to ICU for the continuation of resuscitative measures. Lungs were ventilated with synchronized intermittent ventilation (SIMV), midazolam, and morphine infusion for sedation and analgesia; variable rate insulin infusion, blood and blood products were started. Initial investigations revealed deranged renal function test (RFT) (blood urea: 131 mg/dl, serum creatinine 3.9 mg/dl), hypoalbuminemia (2 gm/dl), and hypocalcemia (7.7 mg/dl). A chest X-ray revealed right side lung pleural effusion. During two months, the patient received antibiotics according to culture and sensitivity (ceftriaxone, imipenem, metronidazole), high inotropic support and several attempts to wean from the ventilator. No neuromuscular drugs were administered. During this course of ICU stay, the patient developed motor weakness in all four limbs. The power in lower limbs was 2/5 and 3/5 in the upper limbs. Nerve conduction velocity (NCV) study suggested severe sensorimotor neuropathy. On neurology consultation, oral pyridostigmine 30 mg thrice daily and intramuscular (IM) testosterone analogue 250 mg (Inj. SUSTANON®, Aspen, Dublin) once in every five days was started. There was a gradual improvement in patient's motor power over a few weeks and the patient was discharged with a tracheostomy tube in situ. However, the patient had sudden aspiration at home and died after two months of discharge from the hospital.

Case 2

An 18-year-old male with no known comorbidities was admitted to a private hospital with shortness of breath. Initially, he was managed on high flow nasal cannula and non-invasive ventilation. He was diagnosed with scrub typhus IgM positive before presenting to the present hospital. The high resolution computed tomography of the chest showed areas of consolidation and ground-glass opacities in bilateral lungs with lower lobe predominance. The echocardiography was normal. The patient developed acute respiratory distress syndrome (ARDS) and septic shock. As per records of referring hospital, the patient had a witnessed cardiac arrest and return of spontaneous circulation was achieved in a few minutes. Magnetic resonance imaging (MRI) of the brain was done with the findings suggestive of acute disseminated encephalomyelitis (ADEM) and hypoxic encephalopathy. Electroencephalogram (EEG) showed low voltage β activity. After one month, the patient was shifted to ICU of the present tertiary care hospital. The patient was hemodynamically stable with a tracheostomy placed in situ. Lungs were ventilated with SIMV and supportive ICU management (piperacillin-tazobactam, ceftriaxone, imipenem, colistin as per culture sensitivity) was continued. No neuromuscular blocking drugs were administered. The brain MRI showed multifocal T2/FLAIR hyperintensities involving the subcortical white matter of the bilateral frontal lobe, white matter commissural tracts, brain stem, bilateral cerebellar lobes extending into the cervical cord with minimal patchy diffusion restriction and no blooming on fast field echo (FFE) used to rule out haemorrhage or calcification and no post-contrast enhancement suggestive of subacute to chronic changes. Neurology consultation was done for the weakness of both upper limbs and lower limbs. The power of both upper and lower limbs was 1/5. NCV study showed bilateral upper limb and lower limb motor neuropathy. The patient was started on IM testosterone analogue 250 mg (Inj. SUSTANON®, Aspen, Dublin) and tab pyridostigmine 30 mg thrice daily and then after 3 days to 60 mg thrice daily. The motor power of the upper limb improved to 4/5 and lower limb to 2/5. The patient was gradually weaned from a ventilator over two weeks. The patient was shifted from ICU to ward on trach vent. The patient is showed progressive neurological recovery and gained motor power of 4/5 in both upper and lower limbs at three months follow-up.

Discussion

Prolonged ICU stay and ventilator dependence are seen due to respiratory muscle and limb weakness. Early prevention and intervention in the initial 48-72 hours of the disease may be more effective to prevent the development of the CIP. Females are more vulnerable than men because of less muscle mass. The most common risk factors for CIP are malnutrition, sepsis, multi-organ failure, prolonged mechanical ventilation, use of neuromuscular blocking drugs, hyperglycemia, and insulin resistance. Mechanical ventilation carries a complex risk factor, because of ventilator-induced diaphragmatic weakness and injury.[7] In case 1, the risk factors involved in CIP were sepsis, hyperglycemia, deranged renal function test, prolonged ventilation, and prolonged use of inotropes. In case 2, the risk factors for CIP were prolonged mechanical ventilation, muscle immobilization, muscle atrophy, and cardiac arrest. An improvement was observed in our patients following hormonal testosterone derivatives and pyridostigmine therapy.

Testosterone, an anabolic steroid has been shown to increase weight, reduce morbidity, and increase inspiratory muscle strength helping in early weaning off from the ventilator.[8] Researchers have reported a superior role of oral nutritional support with anabolic steroids in malnourished patients with alcoholic hepatitis, burn patients, and chronic obstructive pulmonary disease as compared to only nutritional support. It has been observed that despite similar weight gain in both the groups, patients receiving both nutritional support and anabolic steroids had larger improvement in respiratory muscle strength and improved functional capacity of the patient.[89] Anabolic steroids increase muscle protein synthesis and stimulate the growth hormone and insulin-like growth factors.[9]

Another important point is the time of administering testosterone (i.e., anabolic steroids), which should be in the recovery phase of illness in ICU patients. It implies that the patient should not have any ongoing organ support, inotropes or vasopressors administration, and no increasing inflammatory markers. Lowering of testosterone levels in critically ill patients is an energy conservation mechanism since the body is under stress. The addition of anabolic steroids in the recovery phase after critical illness patients, assist them to regain their muscle strength with the addition of early mobility programs.[10]

Pyridostigmine is a carbamate inhibitor of acetylcholinesterase and is mainly used to treat myasthenia gravis. Pyridostigmine indirectly increases the concentration of acetylcholine at the neuromuscular junction and promotes increased cholinergic nicotinic receptor activation. The increase in acetylcholine levels in neuromuscular junctions improves motor tone. Ozyurek H et al. used pyridoxine and pyridostigmine for the treatment of vincristine-induced cranial and peripheral neuropathies in a 4-year-old boy who was diagnosed with B precursor acute lymphoblastic leukemia (ALL). During the treatment, the patient developed severe weakness in lower extremities, bilateral foot drop, and reduced deep tendon reflexes. The addition of pyridostigmine in the treatment resulted in clinical improvement of neuropathic signs of the patient more rapidly than those managed only by the elimination of vincristine.[11]

In addition, nutritional and supportive treatment reduced the patient's ICU stay and improved the prognosis. In prolonged critical illness, there is an imbalance between catabolic and anabolic hormones that leads to the loss of lean body mass. CIP has medical, economical, and psychosocial adverse outcomes for the patient and community. There are limited medical interventions available now for the treatment.[10]

To conclude, patients with CIP were successfully managed with pyridostigmine and hormonal therapy initially and later with pyridostigmine only. The role of nutrition, physiotherapy, and supportive care is important for a successful outcome.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

1. Divatia JV, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S. Intensive care in India: The Indian intensive care case mix and practice patterns study Indian J Crit Care Med. 2016:216–25
2. Witt NJ, Zochodne DW, Bolton CF, Grand'Maison F, Wells G, Young GB, et al Peripheral nerve function in sepsis and multiple organ failure Chest. 1991;99:176–84
3. Tennilä A, Salmi T, Pettilä V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis Intensive Care Med. 2000;26:1360–3
4. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al Paresis acquired in the intensive care unit: A prospective multicenter study JAMA. 2002;288:2859–67
5. Coakley JH, Nagendran K, Yarwood GD, Honavar M, Hinds CJ. Patterns of neurophysiological abnormality in prolonged critical illness Intensive Care Med. 1998;24:801–7
6. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy (Protocol) Cochrane Database Syst Rev. 2009;1:CD006832
7. Yang T, Li Z, Jiang L, Wang Y, Xi X. Risk factors for intensive care unit-acquired weakness: A systematic review and meta-analysis Acta Neurol Scand. 2018;138:104–14
8. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy Cochrane Database Syst Rev. 2014;1:CD006832
9. Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, et al The sick and the weak: Neuropathies/myopathies in the critically ill Physiol Rev. 2015;95:1025–109
10. Anstey M, Desai S, Torre L, Wibrow B, Seet J, Osnain E. Anabolic steroid use for weight and strength gain in critically ill patients: A case series and review of the literature Case Rep Crit Care. 2018;2018:4545623
11. Ozyurek H, Turker H, Akbalik M, Bayrak AO, Ince H, Duru F. Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy Pediatr Hematol Oncol. 2007;24:447–52
Keywords:

Critical illness polyneuropathy; intensive care unit; pyridostigmine; testosterone

© 2021 Journal of Anaesthesiology Clinical Pharmacology | Published by Wolters Kluwer – Medknow